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Vascular endothelial growth factor accelerates renal recovery The hemolytic uremic syndrome (HUS) and the re-
in experimental thrombotic microangiopathy. lated thrombotic microangiopathies (TMAs) are clinical
Background. Renal microvascular injury characterizes throm- syndromes characterized by thrombocytopenia, non-botic microangiopathy (TMA). The possibility that angiogenic
immune hemolytic anemia, and variable degrees of renalgrowth factors may accelerate recovery in TMA has not been
studied. insufficiency [1, 2]. Most cases of HUS are secondary
Methods. TMA was induced in rats by the selective right to enteric infection with certain verotoxin-expressing
renal artery perfusion of antiglomerular endothelial cell IgG strains of Escherichia coli (particularly O157:H7) [3].(30 mg/kg). Twenty-four hours later, rats received vascular
Pathologically, the hallmark of HUS is injury to theendothelial growth factor (VEGF121, 100 mg/kg/day) or vehicle
(control) daily until day 14. To evaluate renal function, the glomerular and other renal microvascular endothelium
unperfused left kidney was removed at day 14, and rats were and is characterized by arteriolar and capillary swelling,
sacrificed at day 17. apoptosis, and/or detachment of endothelial cells withResults. The induction of TMA was associated with loss
intracapillary thrombi formation [2, 4]. While most pa-of glomerular and peritubular capillary endothelial cells and
tients with E. coli-associated HUS recover from the acutedecreased arteriolar density at day 1. Some spontaneous capil-
lary recovery was present by day 17; however, repair was incom- illness, as many as 20 to 40% will show evidence of
plete, and severe tubulointerstitial damage occurred. The lack persistent renal injury, as manifested by proteinuria, hy-
of complete microvascular recovery was associated with re-
pertension, or chronic renal disease [5–8]. The long-termduced VEGF immunostaining in the outer medulla. VEGF-
prognosis correlates with the extent of the initial histo-treated rats had more glomeruli with intact endothelium, less
glomerular ischemia (collapsed glomeruli), and greater peritu- logic damage [8].
bular capillary density with less peritubular capillary loss. This Recently, we developed a model of TMA in the rat
was associated with less tubulointerstitial fibrosis, less cortical
by the selective renal artery perfusion with an antiendo-atrophy, and improved renal function.
thelial cell antibody. This model is characterized by se-Conclusions. VEGF accelerates renal recovery in this exper-
imental model of TMA. These studies suggest that angiogenic vere glomerular and peritubular capillary endothelial in-
growth factors may provide a new therapeutic strategy for jury resulting in all of the histologic features of TMA.
diseases associated with endothelial cell injury.
Similar to severe forms of HUS, the renal injury does
not resolve, and progressive glomerular and tubulointer-
stitial damage results [9].
We postulated that the incomplete resolution of renal
injury in our TMA model may be due to inadequate
1 See Editorial by Remuzzi, p. 2594 recovery of the glomerular and peritubular capillaries.
Recently, the endothelial cell mitogen vascular endothe-Key words: angiogenesis, ischemia, endothelium, hemolytic uremic
syndrome. lial growth factor (VEGF) [10] has been shown to be
stimulate angiogenesis in animal models of peripheral
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crovasculature and improve histology and renal function To obtain baseline data on the severity of the capillary
injury at day 1, a separate set of rats with TMA (N 5 4)in the TMA model.
was sacrificed at day 1, and sagittal sections of the kidney
were obtained for analysis. Control animals for this part
METHODS
of the study consisted of rats perfused with nonimmu-
Experimental thrombotic microangiopathy model nized goat IgG in PBS, pH 7.2 (N 5 4), and sacrificed
at day 1.Thrombotic microangiopathy was induced in male
Sprague-Dawley rats (280 to 330 g; Simonsen Labora-
Renal histologytory, Gilroy, CA, USA) by selective perfusion of the
right kidney with antiglomerular endothelial cell (GEN) Kidneys obtained at the time of sacrifice were divided
longitudinally, and one half of the kidney was fixed inIgG (30 mg/kg body weight). The characteristics of anti-
GEN antibody [9] and the technique of selective right methyl Carnoy’s solution, processed, paraffin embedded,
sectioned (4 mm), and stained with the periodic acid-renal artery perfusion [17] have been described pre-
viously. Although the antibody was raised against glo- Schiff (PAS) reagent with hematoxylin counterstain. Ad-
ditional 4 mm sections were immunostained using anmerular endothelial cells, it also cross-reacts to a lesser
degree with the endothelium of the peritubular capillar- indirect avidin-biotin immunoperoxidase method with
the following primary antibodies: aSM-1 (1A4), a mono-ies [9]. Validation of the effectiveness of the perfusion
was established in all animals by performing a survival clonal IgG2a to a-smooth muscle actin (a-SMA) (Sigma
Chemical Co., St. Louis, MO, USA); RECA-1 (a mono-cortical biopsy 10 minutes after perfusion and verifying
the presence of goat IgG by immunofluorescence. All clonal IgG1 antibody specific for a 60 kD rat endothelial
cell membrane antigen) [20], and JG-12, a monoclonalrats perfused with anti-GEN IgG exhibited diffuse glo-
merular staining for goat IgG along all capillary walls in antibody to rat endothelial cells (characterized later in
this article). VEGF was stained with affinity-purified rab-a coarse, uninterrupted pattern consistent with staining
of GEN. Peritubular capillaries and arterioles in the kid- bit anti-VEGF polyclonal antibody (Santa Cruz Biotech,
Inc., Santa Cruz, CA, USA). Controls included omissionney were also positive. Quantitative immunofluores-
cence densitometry of the goat IgG deposition in glomer- of the primary antibody or substitution with an irrelevant
antibody of the same species and isotype.uli was also performed using a Leitz immunofluorescence
microscope with visual output connected to a photomul- Capillary endothelial proliferation was detected by
double immunostaining tissue sections with the anti-tiplier as previously described. The mean quantitated
fluorescence was considered adequate for the study [18]. endothelial cell antibody (JG-12) and an antibody to the
proliferating nuclear cell antigen (PCNA; 19A2; Coulter
Experimental protocol Immunology, Hialeah, FL, USA). Controls consisted of
substituting the primary antibody with an irrelevantThe studies were designed to determine whether
VEGF hastens capillary repair and renal recovery in the monoclonal antibody of the same isotype as described
previously [21].TMA model. Rats with TMA were therefore randomized
to receive VEGF or vehicle beginning one day after
Preparation and characterization of JG-12 antibody toperfusion of the anti-GEN antibody. VEGF or vehicle
rat microvascular endotheliuminjections were continued daily for 14 days. At 14 days,
the normal nonperfused kidney was removed so that Rat glomeruli were isolated by graded sieving, and a
membrane protein fraction was prepared by incubationsubsequent renal function measurements would reflect
only that of the diseased kidney. Rats underwent sacrifice in 200 mmol/L Na2CO3 (pH 5 11) followed by phase
separation in Triton X-114, as described [22]. Mono-three days later, at which time blood and renal tissues
were collected. clonal antibodies were raised [23] and screened for selec-
tive endothelial staining pattern on unfixed cryostat sec-VEGF121 (50 mg/kg/injection) was administered subcu-
taneously twice a day from days 1 through 14. Control tions of normal rat kidneys and clone JG-12 was selected.
Monoclonality was verified by three rounds of limitinganimals received vehicle [phosphate-buffered saline (PBS),
pH 7.2, control group]. The VEGF121 isoform was used, dilution, and the antibody was further shown to be of
the IgG1 class.as it is the only isoform of VEGF that has no heparin
binding and therefore can result in therapeutically effec- To characterize the antigen of the JG-12 antibody, rat
glomeruli were isolated, dissolved in sodium dodecyltive plasma levels when administered subcutaneously
[19]. The dose of VEGF121 used has been found to result sulfate (SDS) sample buffer, the protein lysate separ-
ated by SDS-polyacrylamide gel electrophoresis (SDS-in peak VEGF levels of 50 ng/mL at 100 minutes and 5
ng/mL at 6 hours, which are effective levels to stimulate PAGE), and transferred to nitrocellulose [23]. Immu-
noblotting was performed using alkaline phosphataseangiogenesis in a rat ischemic hindlimb model (data not
shown). coupled with sheep anti-mouse IgG (Promega, Madison,
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Fig. 1. Characteristics of JG-12 antibody. (a) Immunoblotting using alkaline phosphatase coupled with sheep anti-mouse IgG. JG-12 bound to a
70 kD protein in glomerular lysates. Lane A, Coomassie-Blue stained pattern of proteins in glomerular lysate. Lane B, Control incubation with
irrelevant monoclonal antibody of the same subtype as JG-12 (that is, IgG1). Lane C, Immunoblot with monoclonal antibody JG-12, that specifically
labels a broad 70 kD band. (b) Immunoelectron microscopy of renal glomeruli (CL, capillary lumen; GBM, glomerular basement membrane; P,
podocyte; US, urinary space). JG-12 labeling was strictly confined to the luminal aspect of the endothelial cells. (c and d). Renal endothelial cell
staining of normal rat kidneys with RECA-1 (c) and JG-12 (d) show a similar staining pattern (3160).
WI, USA) and developed by 59-bromo-4-chloro-3-indolyl Quantitation of morphology and
immunohistochemical stainingphosphate toluidine salt. JG-12 was found to specifically
bind a 70 kD protein in the glomerular lysates (Fig. 1a). Using computer-assisted image analysis software (Op-
Similar results were obtained in the lung (data not shown). timas, version 6.2; Media Cybernetics, Silver Springs,
By immunohistochemistry, intense labeling of glomer- MD, USA), we measured the total area of the cortex, the
ular and peritubular capillaries was observed, and the outer medulla, and cortical thickness on the longitudinal
pattern was similar to that seen with the RECA-1 anti- section of each biopsy. Cortical thickness was defined as
body (Fig. 1 c, d). Labeling intensity was highest in the the mean length between the renal surface and the most
capillaries and decreased with the caliber of the blood inner (juxtamedullary) glomeruli utilizing 10 measure-
vessel, and unlike RECA-1, staining was insignificant in ments for each biopsy. Glomerular sclerosis was defined
arterial vessels. By immunoelectron microscopy on renal as segmental or global capillary collapse with increased
glomeruli, the specific labeling of the endothelial cells matrix deposition in over 25% of glomerular surface
was apparent, especially in oblique sections that exposed area. Glomerular collapse (which is generally considered
the endothelial cell bodies (Fig. 1b). Labeling was strictly a measurement of glomerular ischemia) was defined as
confined to the luminal aspect of the endothelial cells, shrinkage of the glomerular tuft to one half or less of
the diameter of Bowman’s capsule. For each biopsy, alland no other component of the glomerulus was labeled.
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glomeruli (N . 140) on the whole longitudinal section Statistical methods
of a kidney were examined [24]. Tubulointerstitial injury Values are expressed as mean 6 SE. Differences be-
was defined as increased tubular cellularity, basement tween the VEGF and vehicle-treated groups were evalu-
membrane thickening, tubular dilation, atrophy, slough- ated with the unpaired Student’s t-test. When more than
ing, or interstitial widening and was graded two different two groups were compared, analysis was by analysis of
ways. The first method used a blinded semiquantitative variance (ANOVA) with the Bonferonni correction for
scoring system (0 through 5) as follows: grade 0 5 no multiple comparisons. The correlation between capillary
tubulointerstitial injury present; grade 1 5 ,10%; grade rarefaction and tubulointerstitial injury was evaluated
2 5 10 to 25%; grade 3 5 26 to 50%; grade 4 5 51 to by linear regression.
75%; and grade 5 5 .75% of tubulointerstitium injured
[24]. For each biopsy, the entire cortical and outer medul-
RESULTSlar regions on longitudinal section were evaluated under
low power (3100) through 10 3 10 eyepiece grid Perfusion with anti-GEN IgG results in microvascular
(1 mm2), and a mean score per biopsy was calculated endothelial injury with tissue damage at day 1
[25]. The second method used computer-assisted image Control rats perfused with normal goat IgG had nor-
analysis software (Optimas), in which the percentage mal capillary morphology, no capillary rarefaction (score
area of tubulointerstitial injury was measured utilizing 0), and normal histology (PAS staining) at day 1. Arteri-
the entire cortex and outer medulla on longitudinal sec- oles and interlobular arteries in the cortex were also
tion at 350 magnification. All analyses were performed intact with a density of 4.95 6 0.31 vessels/mm2 (Table 1).
blinded. In contrast, the infusion of anti-GEN IgG resulted in
injury to both glomerular and peritubular capillary endo-Assessment of microvasculature
thelium, as reported previously [9]. At day 1, there was
Changes in endothelial cell morphology and density extensive loss of peritubular capillaries (capillary rar-
were confirmed by staining tissue sections with two anti-
efaction score, 41.5 6 2.8; Fig. 2). Capillary loss was
bodies (RECA-1 and JG-12) to different endothelial cell
particularly severe in the outer medullary area (rarefac-
antigens. Although changes in capillary density appeared
tion score 54.0 6 2.6) compared with that in the cortex
qualitatively similar using both antibodies, JG-12 gave
(score 29.0 6 3.1). In glomeruli, a decrease in JG-12a lower background and more intense staining than
staining (,75% of glomerular tuft) was present in 37.2 6RECA-1. Therefore, only data obtained with JG-12 are
3.8% of glomeruli consistent with acute GEN loss. Arte-shown (Fig. 1). Capillary loss was assessed using a rar-
rioles and interlobular arteries in the cortex also fre-efaction index [26]. JG-12–immunostained sections were
quently demonstrated denuded or swollen endothelium.examined through 10 3 10 eyepiece grid under a 310
There was a decrease in a-smooth muscle actin–positiveobjective. At this magnification, the grid covered an area
arterioles and interlobular arteries in the cortex (2.36 6of 1 mm2. Each square (0.1 mm2) within the grid that
0.26 vessels/mm2) compared with controls (4.95 6 0.31did not contained JG-12–positive cells was scored. At
vessels/mm2, P , 0.0001; Fig. 2). The renal microvascularleast 50 fields in the cortex and outer medulla were exam-
injury was accompanied by thrombi in the glomerularined on the longitudinal section of each kidney, and a
capillary loops and tubular damage with tubular necrosis,mean score per biopsy was calculated. The minimum
sloughing of tubular epithelial cells, and intratubularpossible capillary score is 0, and the maximum score is
casts (PAS staining; Fig. 2).100, where 100 would indicate a complete absence of
In control rats perfused with normal IgG, VEGF ex-JG-12–positive cells [26]. Glomeruli with intact endothe-
pression was prominent in proximal tubules, the medul-lium were defined when strong staining for JG-12 was
lary thick ascending limb, and collecting ducts in thepresent in over 75% of the glomerular tuft. Renal arteri-
outer medulla and medullary rays. Glomeruli showedoles and interlobular arteries were identified by a-
weak staining in glomerular epithelial cells. In rats withsmooth muscle actin staining, and the arteriolar density
TMA, VEGF expression was increased focally in tubuleswas reported as the number of arterioles and interlobular
in the cortex and in glomeruli at day 1; the latter isarteries per mm2 cortex.
localized to visceral glomerular epithelial cells as re-
Additional measurements ported previously [9]. However, in the medulla, VEGF
expression was markedly decreased compared with con-Blood urea nitrogen (BUN) was determined colori-
trol rats (Fig. 3 a, b).metrically with a commercial kit (Sigma Diagnostics, St.
Louis, MO, USA). Urinary nitrate (NO32) plus nitrite
Effect of VEGF on renal recovery in TMA(NO22) excretion was measured by conversion of nitrate
Rats with TMA were randomized to receive VEGFto nitrite using nitrate reductase followed by the addition
of the Griess reagent (Clontech, Palo Alto, CA, USA). or vehicle beginning at day 1 after induction of disease,
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Table 1. Effect of vascular endothelial growth factor (VEGF) treatment in experimental thrombotic microangiopathy (TMA)
Day 1 Day 17
Control TMA Vehicle VEGF group P valuea
Arteriole and interlobular
artery density /mm2 4.9560.31 2.3660.26 3.2560.38 4.5860.23 0.014
Capillary rarefaction scorea 0 41.562.8 4.2861.1 1.6760.4 0.001
Glomeruli with intact
endothelium % 100 62.863.8 80.063.0 90.662.7 0.025
Glomerulosclerosis % 0 ND 14.762.9 7.862.7 0.116
Collapsed glomeruli % 0 ND 5.3061.20 1.5460.45 0.015
Cortical thickness mm 1.5260.03 ND 1.1160.02 1.3260.05 0.003
Tubulointerstitial injury
% Area 0 ND 25.764.6 10.263.7 0.027
Score 0 ND 3.1260.43 1.7260.30 0.023
ND is not done. Data are mean 6 SE.
a Comparison of vehicle-treated to VEGF-treated groups at day 17
Fig. 2. Renal histologic injury at day 1 in experimental thrombotic microangiopathy (TMA). (a) At day 1, rats with TMA display thrombi in
glomerular capillary loops, tubular necrosis, sloughing of tubular epithelial cells, and tubular cast formation (PAS, 3200). (b) A loss of glomerular
and peritubular capillary endothelial cell staining is present at day 1 (JG-12 immunostaining, 3200). (c and d) Compared with control animals
(c), arterioles and interlobular arteries, identified by a-smooth muscle actin (a-SMA) staining, are decreased in rats with TMA (d, 3100).
and the injections were continued until day 14. At this The tubulointerstitial injury was particularly severe in
the outer medulla and medullary rays. VEGF expressiontime, the nonperfused kidney was removed so that any
observed changes in renal function would reflect the remained decreased in the outer medulla, especially at
sites of interstitial fibrosis (Fig. 3c). The focal areas ofdiseased kidney, and the rat was followed for three more
days until sacrifice. Examination of the diseased kidney increased VEGF immunostaining in glomeruli and outer
cortex observed at day 1 were no longer present. Theat day 17 in the vehicle-treated rats documented marked
atrophy or dilation of tubules and interstitial fibrosis. tubulointerstitial injury was also associated with signifi-
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Fig. 3. Vascular endothelial growth factor (VEGF) expression in experimental thrombotic microangiopathy (TMA). (a) In control rats administered
nonimmune IgG, VEGF immunostaining is prominent in tubules in the outer medulla and medullary rays. (b) In rats with TMA at day 1, there
is a loss of VEGF in the outer medulla and focal increases in the cortex. (c) At day 17, vehicle-injected rats with TMA continued to show decreased
VEGF expression, particularly at sites of tubulointerstitial injury. (350).
cantly reduced renal function, with a mean BUN of 172 reduction in the number of glomeruli showing collapse
of the tuft, consistent with less glomerular ischemia.mg/dL (compared with normal values of 24 6 0.4 mg/dL,
P , 0.01). Glomerular sclerosis tended to be lower in the VEGF-
treated group, but the difference between the VEGFIn contrast, VEGF-treated rats had significantly less
(7.8 6 2.7%) and vehicle groups (14.7 6 2.9%) did nottubulointerstitial injury (PAS staining) in diseased kid-
reach statistical difference (Table 1).neys at day 17 (Fig. 4 a, b). Both the percentage area of
Peritubular capillary density was also greater in thetubulointerstitial injury (10.2 6 3.7%) and the mean
VEGF group (Fig. 4 c, d and Table 1). In particular,score (1.72 6 0.30) were significantly less in the VEGF
VEGF-treated rats showed less capillary rarefaction thangroup compared with the vehicle group (25.7 6 4.6%,
vehicle-treated controls (Table 1). Cortical arteriole and3.12 6 0.43, P , 0.05, respectively). VEGF-treated ani-
interlobular artery density (a-SMA staining) was alsomals also had less cortical atrophy, as reflected by preser-
significantly greater in the VEGF group (4.58 6 0.23vation of the cortical thickness (P , 0.01; Table 1). The
vessels/mm2) than in the vehicle group (3.25 6 0.38 ves-BUN was lower by a factor of 2.5 in the VEGF group
sels/mm2, P 5 0.01) and was similar to that observed incompared with the vehicle group (BUN 68 6 8 vs. 172 6
the day 1 control rats (4.95 6 0.31 vessels/mm2, P 540 mg/dL, P 5 0.03; Fig. 5). Five of the six control rats
NS by analysis of variance with correction for multiplehad BUN levels greater than 100 mg/dL versus one of
comparisons; Fig. 4 e, f). Peritubular capillary prolifera-six of VEGF-treated rats.
tion (identified by JG-12 and PCNA double staining)The differences between VEGF- and vehicle-treated
was present in both vehicle- and VEGF-treated groups.TMA rats are summarized in Table 1.
However, proliferating cells were rare in both VEGF
Effect of VEGF on endothelial cell recovery (0.04 6 0.01 cells/mm2) and vehicle groups (0.02 6 0.003
cells/mm2), and there was no statistical difference be-Vehicle-treated rats had a substantial recovery of both
the glomerular and peritubular capillary endothelium at tween two groups (P . 0.05) at day 17 (which was 3
days after the VEGF infusion was stopped). Endothelialday 17 (Table 1). However, VEGF-treated rats showed
a significantly greater recovery. The number of glomeruli cell proliferation was most commonly observed in or
near the sites of tubulointerstitial injury. Glomerularwith positive staining for endothelial cells was greater
in VEGF-treated rats (1.98 6 0.10 glomeruli/mm2) com- endothelial cell proliferation was minimal in both groups.
Since VEGF-mediated angiogenesis acts through thepared with vehicle-treated rats (1.62 6 0.10 glomeruli/
mm2, P , 0.02). The percentage of glomeruli with endo- nitric oxide system, we examined the effect of VEGF on
urinary nitrite excretion. VEGF-treated rats had signifi-thelial cell staining was also greater in the VEGF group
compared with the vehicle group (P , 0.02; Table 1). cantly greater excretion of urinary nitrates/nitrites than
vehicle-treated controls (1913 6 180 vs. 786 6 400 nmol/VEGF treatment was also associated with a threefold
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Fig. 4. Effect of VEGF on experimental TMA. VEGF-treated rats had less tubulointerstitial injury (a, PAS) than vehicle-injected rats (b) at day
17. Glomerular collapse (b, arrows) was more prominent in vehicle-injected rats. Both capillary density (JG-12 staining, c and d) and arteriolar
density (a-SMA staining, e and f ) were greater in the VEGF-treated group (c and e) compared to vehicle-injected rats (d and f, 3100).
day, respectively, P 5 0.02) Indeed, the urinary nitrate/ lointerstitial injury (TI) injury (r 5 0.60, P 5 0.038, Fig.
nitrite excretion in VEGF-treated rats approached that 6). The degree of capillary loss (capillary rarefaction
observed in the rats that had received nonimmune IgG score) also correlated with BUN levels (r 5 0.63, P 5
(2401 6 243 nmol/day). 0.026).
Correlation of capillary rarefaction with
DISCUSSIONtubulointerstitial injury and renal function
In this study, we tested the hypothesis that the adminis-Capillary rarefaction was most pronounced in areas
tration of an angiogenic factor may accelerate renal re-of tubulointerstitial injury in both vehicle- and VEGF-
covery in a model of TMA. TMA was induced by thetreated rats. Within individual animals, the degree of
capillary rarefaction correlated with the degree of tubu- selective renal artery perfusion of an antibody to glomer-
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by the presence of glomerular thrombi and tubulointer-
stitial damage in the diseased rats as compared with
control rats that were perfused with nonimmune IgG.
Marked glomerular and peritubular capillary loss was
also documented in the diseased rats by staining for
two different endothelial cell antigens (identified by the
RECA-1 and JG-12 antibodies). This strongly suggests
that the loss of endothelial cell staining was not simply
due to the loss of a particular endothelial cell antigen
secondary to the disease process.
Fig. 5. VEGF treatment improves tubulointerstitial injury and renal
The most severe tubular injury at day 1 was in thefunction in experimental TMA. The percentage of (A) tubulointersti-
tial injury was lower in VEGF treated rats at day 17, and (B) BUN outer medulla and medullary rays, which is consistent
levels were also reduced 2.5-fold. with studies suggesting that tubular cells in these region
are the most susceptible to ischemic injury [28, 29]. These
tubules in the outer medulla and medullary rays also
constitutively express VEGF, and it was therefore not
surprising to find a reduction of VEGF staining in dis-
eased animals at this time point.
Since VEGF has trophic, prosurvival, and angiogenic
properties for endothelial cells [30, 31], the acute loss of
VEGF in the tubules at day 1 provided a rationale for
investigating whether the infusion of VEGF could hasten
endothelial recovery and improve overall outcome. We
therefore administered VEGF121 to rats with this model
of TMA from day 1 to day 14 in order to determine
whether reconstitution of this angiogenic growth factor
could improve renal recovery. To determine whether
VEGF treatment could improve renal function in theFig. 6. Capillary rarefaction correlates significantly with tubulointer-
stitial fibrosis in experimental TMA. Individual values for VEGF- diseased kidney, we removed the normal, nonperfused
treated rats (s) and vehicle-injected rats (j) are shown. kidney at day 14 and determined the renal function three
days later.
Vehicle-treated rats showed a remarkable recovery
of the glomeruli, which is consistent with a prior studyular endothelial cells that also cross-reacts with peritubu-
lar capillary and renal arterial endothelium. We have documenting an early glomerular endothelial cell prolif-
erative response in conjunction with up-regulation ofpreviously shown that this antibody leads to an acute
complement-dependent apoptosis of endothelial cells podocyte VEGF expression [9]. There was also a sub-
stantial recovery of the peritubular capillaries in vehicle-[27]. Consistent with this finding was the observation
in the current study of marked loss of glomerular and treated rats. Nevertheless, the recovery of the peritubu-
lar capillaries was incomplete, and at day 17, substantialperitubular capillary staining at day 1 in association with
significant glomerular and tubulointerstitial injury. Rats tubulointerstitial fibrosis and renal failure were present.
The observation that VEGF expression remained lowwere then randomized to receive VEGF or vehicle for
14 days, and 3 days later, the rats were sacrificed. While in the outer medulla in conjunction with the inadequate
capillary repair in vehicle-treated rats suggested that theclearly some spontaneous capillary repair had occurred
in the control kidneys, recovery of the glomerular and continued lack of this angiogenic factor might have con-
tributed to the poor recovery.peritubular capillary network was incomplete, and there
was significant chronic tubulointerstitial fibrosis and re- Vascular endothelial growth factor-treated rats had a
more complete recovery of the glomerular endotheliumnal failure. In contrast, VEGF-treated rats had signifi-
cantly greater recovery of the microvasculature, and this as well as more marked recovery of the peritubular capil-
laries compared with vehicle-infused rats. Capillary rar-was associated with better renal function and less fibrosis.
To our knowledge, this is the first time that an angiogenic efaction was threefold less in VEGF-infused rats, and
capillary density was visibly improved (Fig. 4 a, b).factor has been used successfully to treat kidney disease.
Since the study design was to determine whether VEGF-infused rats also had markedly less tubulointer-
stitial fibrosis, preservation of cortical volume (as re-VEGF could accelerate capillary repair, treatment was
not started until 24 hours after induction of disease. At flected by cortical thickness), and BUN levels that were
2.5-fold lower than control rats. Further evidence for athis time, renal injury is well established, as evidenced
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